JP2013503134A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503134A5
JP2013503134A5 JP2012526048A JP2012526048A JP2013503134A5 JP 2013503134 A5 JP2013503134 A5 JP 2013503134A5 JP 2012526048 A JP2012526048 A JP 2012526048A JP 2012526048 A JP2012526048 A JP 2012526048A JP 2013503134 A5 JP2013503134 A5 JP 2013503134A5
Authority
JP
Japan
Prior art keywords
compound
formula
anhydrous crystalline
crystalline form
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012526048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503134A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/062420 external-priority patent/WO2011023733A1/en
Publication of JP2013503134A publication Critical patent/JP2013503134A/ja
Publication of JP2013503134A5 publication Critical patent/JP2013503134A5/ja
Pending legal-status Critical Current

Links

JP2012526048A 2009-08-27 2010-08-25 無水形態のピリジン誘導体 Pending JP2013503134A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
US61/237,435 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015139845A Division JP6404186B2 (ja) 2009-08-27 2015-07-13 無水形態のピリジン誘導体

Publications (2)

Publication Number Publication Date
JP2013503134A JP2013503134A (ja) 2013-01-31
JP2013503134A5 true JP2013503134A5 (https=) 2013-09-19

Family

ID=42790943

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012526048A Pending JP2013503134A (ja) 2009-08-27 2010-08-25 無水形態のピリジン誘導体
JP2015139845A Active JP6404186B2 (ja) 2009-08-27 2015-07-13 無水形態のピリジン誘導体
JP2017114602A Pending JP2017193564A (ja) 2009-08-27 2017-06-09 無水形態のピリジン誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015139845A Active JP6404186B2 (ja) 2009-08-27 2015-07-13 無水形態のピリジン誘導体
JP2017114602A Pending JP2017193564A (ja) 2009-08-27 2017-06-09 無水形態のピリジン誘導体

Country Status (17)

Country Link
US (1) US8796269B2 (https=)
EP (1) EP2470545B1 (https=)
JP (3) JP2013503134A (https=)
KR (1) KR20120056258A (https=)
CN (1) CN102639536B (https=)
AU (1) AU2010288502B2 (https=)
CA (1) CA2772168C (https=)
DK (1) DK2470545T3 (https=)
EA (1) EA021411B1 (https=)
ES (1) ES2440938T3 (https=)
IL (1) IL217922A (https=)
IN (1) IN2012DN01292A (https=)
MX (1) MX2012002369A (https=)
PL (1) PL2470545T3 (https=)
SG (1) SG178231A1 (https=)
WO (1) WO2011023733A1 (https=)
ZA (1) ZA201200812B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2470545T3 (pl) * 2009-08-27 2014-03-31 Nerre Therapeutics Ltd Bezwodne postaci pochodnej pirydyny
EP3915560A1 (en) 2014-06-25 2021-12-01 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
SMT201900719T1 (it) * 2015-05-18 2020-01-14 Nerre Therapeutics Ltd Antagonista del recettore nk-1/nk-3 per il trattamento delle vampate di calore
CA3044773A1 (en) * 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 activators
AU2019233606B2 (en) 2018-03-14 2024-10-03 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
PE20221167A1 (es) 2019-11-15 2022-07-25 Kandy Therapeutics Ltd Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2-metilfenil)piridin-3-amina, un intermediario clave de nt-814
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025261856A1 (en) * 2024-06-18 2025-12-26 Bayer Consumer Care Ag Improved process for producing an elinzanetant precursor
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
NZ541243A (en) * 2003-01-31 2008-04-30 Hoffmann La Roche New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
RU2347777C2 (ru) * 2003-07-03 2009-02-27 Ф.Хоффманн-Ля Рош Аг Двойные агонисты nk1/nk3 для лечения шизофрении
EA013909B1 (ru) * 2005-09-09 2010-08-30 Смитклайн Бичам Корпорейшн Пиридиновые производные и их применение для лечения психотических расстройств
KR20100101051A (ko) * 2007-12-11 2010-09-16 씨아이피엘에이 엘티디. 조피클론 결정성 다형체, 이들의 제조 공정 및 이들의 약제 조성물
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
PL2470545T3 (pl) * 2009-08-27 2014-03-31 Nerre Therapeutics Ltd Bezwodne postaci pochodnej pirydyny
JP6342662B2 (ja) * 2014-01-29 2018-06-13 京セラ株式会社 ドリルおよびそれを用いた切削加工物の製造方法

Similar Documents

Publication Publication Date Title
JP2013503134A5 (https=)
TWI660956B (zh) 調節蛋白質激酶之化合物的合成
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
JP2010501519A5 (https=)
IL214086A (en) Malt salt of n- {4 - {[7,6- bis (methyllaxy) quinoline-4-yl] oxy} phenyl) - n- (4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms for cancer treatment
FI2534153T4 (fi) 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja
JP2015010091A5 (https=)
JP2011168587A5 (https=)
RU2009136593A (ru) Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у илекопитаюших
JP2014524442A5 (https=)
JP2016065042A5 (https=)
JP2014501282A5 (https=)
JP2010516681A5 (https=)
JP2020511467A5 (https=)
JP2009537498A5 (https=)
JP2014530818A5 (https=)
JP2018531280A5 (https=)
JP2012531408A5 (https=)
CA2729266A1 (en) A novel molecular sieve composition emm-13, a method of making and a process of using the same
JP2011529440A5 (https=)
JP2015522589A5 (https=)
JP2013541592A5 (https=)
RU2015106137A (ru) Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения
JP2012533550A5 (https=)
JP2020536893A5 (https=)